{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:12Z","timestamp":1792511592427,"version":"4.5.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1\u20130208"],"award-info":[{"award-number":["P1\u20130208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P4\u20130127"],"award-info":[{"award-number":["P4\u20130127"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["Z1\u20131859"],"award-info":[{"award-number":["Z1\u20131859"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.biopha.2022.112924","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T23:43:15Z","timestamp":1649374995000},"page":"112924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Cell models for Alzheimer\u2019s and Parkinson\u2019s disease: At the interface of biology and drug discovery"],"prefix":"10.1016","volume":"149","author":[{"given":"Sandra","family":"Cetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damijan","family":"Knez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Pi\u0161lar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112924_bib1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3389\/fnagi.2021.766587","article-title":"Neurodegenerative diseases and cholesterol: seeing the field through the players","volume":"13","author":"Pfrieger","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/imm.12922","article-title":"Inflammation in CNS neurodegenerative diseases","volume":"154","author":"Stephenson","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2022.112924_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2017.02.006","article-title":"Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support","volume":"vol. 106","author":"Marsh","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2022.112924_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138620708783877753","article-title":"High throughput screening for neurodegeneration and complex disease phenotypes","volume":"11","author":"Varma","year":"2008","journal-title":"Comb. Chem. High. Throughput Screen."},{"key":"10.1016\/j.biopha.2022.112924_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200317522","article-title":"Series introduction: Neurodegeneration: What is it and where are we?","volume":"111","author":"Przedborski","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2022.112924_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci8090177","article-title":"Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches","volume":"vol. 8","author":"Hussain","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3233\/JAD-170149","article-title":"Motor phenotype in neurodegenerative disorders: Gait and balance platform study design protocol for the ontario neurodegenerative research Initiative (ONDRI)","volume":"59","author":"Montero-Odasso","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.biopha.2022.112924_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4088\/JCP.10m06382oli","article-title":"The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: Rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease","volume":"72","author":"Woolley","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112924_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.biopha.2018.12.101","article-title":"Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer\u2019s disease, Parkinson\u2019s disease","volume":"111","author":"Tan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.112924_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2017.06.001","article-title":"Multiple mechanisms of neurodegeneration and progression","volume":"vol. 155","author":"Herrero","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"vol. 20","author":"Guo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-cellbio-100617-062636","article-title":"Intercellular Sp read of protein aggregates in neurodegenerative disease","volume":"vol. 34","author":"Davis","year":"2018","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical neurology and epidemiology of the major neurodegenerative diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.112924_bib15","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.83.11.4044","article-title":"Microtubule-associated protein tau (\u03c4) is a major antigenic component of paired helical filaments in Alzheimer disease","volume":"83","author":"Kosik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2022.112924_bib16","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s12035-020-01945-y","article-title":"Mitochondrial dysfunction: A potential therapeutic target to treat Alzheimer\u2019s disease","volume":"57","author":"Rai","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib17","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"\u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2022.112924_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2020.101752","article-title":"Advancement in the modelling and therapeutics of Parkinson\u2019s disease","volume":"104","author":"Rai","year":"2020","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.biopha.2022.112924_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson\u2019s disease","volume":"vol. 86","author":"Davie","year":"2008","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.biopha.2022.112924_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2017.05.007","article-title":"Cellular models as tools for the study of the role of alpha-synuclein in Parkinson\u2019s disease","volume":"vol. 298","author":"L\u00e1zaro","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib21","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1111\/j.1582-4934.2009.00889.x","article-title":"Neuronal death in Alzheimer\u2019s disease and therapeutic opportunities","volume":"13","author":"Donev","year":"2009","journal-title":"J. Cell. Mol. Med"},{"key":"10.1016\/j.biopha.2022.112924_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084081","article-title":"Dopamine reduction in the substantia nigra of Parkinson\u2019s disease patients confirmed by in vivo magnetic resonance spectroscopic imaging","volume":"9","author":"Gr\u00f6ger","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112924_bib23","doi-asserted-by":"crossref","DOI":"10.1590\/1516-4446-2013-1159","article-title":"Studying neurodegenerative diseases in culture models","volume":"35","author":"Schlachetzki","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.biopha.2022.112924_bib24","unstructured":"EXPERIMENTAL MODELS FOR NEURODEGENERATIVE DISEASES Report of the JPND Action Group. (2014)."},{"key":"10.1016\/j.biopha.2022.112924_bib25","doi-asserted-by":"crossref","unstructured":"LC, W. & M, J. Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38, 87\u2013103 (2015).","DOI":"10.1146\/annurev-neuro-071714-033828"},{"key":"10.1016\/j.biopha.2022.112924_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and alzheimer\u2019s disease","volume":"34","author":"O\u2019Brien","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"& Ekavali. A review on Alzheimer\u2019s disease pathophysiology and its management: An update","volume":"vol. 67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2022.112924_bib28","article-title":"Recent advances by in silico and in vitro studies of amyloid-\u03b2 1-42 fibril depicted a S-shape conformation","volume":"vol. 19","author":"Acosta","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"vol. 297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112924_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnagi.2018.00118","article-title":"The physiological roles of amyloid-\u03b2 peptide hint at new ways to treat Alzheimer\u2019s disease","volume":"vol. 10","author":"Brothers","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48790-1","article-title":"Dynamical decoration of stabilized-microtubules by Tau-proteins","volume":"9","author":"Hervy","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112924_bib32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/157015906776359577","article-title":"Neuronal cell death in Alzheimers disease and a neuroprotective factor","volume":"4","author":"Niikura","year":"2006","journal-title":"Humanin. Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1037\/a0029857","article-title":"The natural history of cognitive decline in Alzheimer\u2019s disease","volume":"27","author":"Wilson","year":"2012","journal-title":"Psychol. Aging"},{"key":"10.1016\/j.biopha.2022.112924_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in Alzheimer\u2019s disease: It\u2019s time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress","volume":"vol. 66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112924_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","article-title":"The revitalized Tau hypothesis on Alzheimer\u2019s disease","volume":"41","author":"Maccioni","year":"2010","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.biopha.2022.112924_bib37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"vol. 14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib38","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2174\/1570159X15666171129100944","article-title":"Alpha-synuclein, Proteotoxicity and Parkinson\u2019s Disease: Search for Neuroprotective Therapy","volume":"16","author":"Ganguly","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","article-title":"\u03b1-Synuclein misfolding and aggregation: Implications in Parkinson\u2019s disease pathogenesis","volume":"vol. 1867","author":"Mehra","year":"2019","journal-title":"Biochim. Et. Biophys. Acta - Proteins Proteom."},{"key":"10.1016\/j.biopha.2022.112924_bib40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4161\/auto.5604","article-title":"Ubiquitination of \u03b1-synuclein and autophagy in Parkinson\u2019s disease","volume":"4","author":"Engelender","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2022.112924_bib41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of tau and alpha-synuclein epitopes in Lewy bodies","volume":"62","author":"Ishizawa","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib42","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134316","article-title":"\u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies","volume":"vol. 709","author":"Henderson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2022.112924_bib44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1471-4159.2004.02423.x","article-title":"Could a loss of \u03b1-synuclein function put dopaminergic neurons at risk?","volume":"vol. 89","author":"Perez","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112924_bib45","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/01.wnl.0000183359.50822.f2","article-title":"Progression of motor impairment and disability in Parkinson disease: A population-based study","volume":"65","author":"Alves","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.112924_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","article-title":"Neurotransmitter receptors and cognitive dysfunction in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"vol. 97","author":"Xu","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.572976","article-title":"Neuroimaging advances in Parkinson\u2019s disease and atypical parkinsonian syndromes","volume":"vol. 11","author":"Saeed","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib48","article-title":"Non-motor extranigral signs and symptoms in Parkinson\u2019s disease","volume":"15","author":"Wolters","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.biopha.2022.112924_bib49","doi-asserted-by":"crossref","unstructured":"Kouli, A., Torsney, K.M. & Kuan, W.-L. Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. in Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects 3\u201326 (Codon Publications, 2018). doi:10.15586\/codonpublications.parkinsonsdisease.2018.ch1.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"10.1016\/j.biopha.2022.112924_bib50","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: A special essay on the 200th Anniversary of the Shaking Palsy","volume":"vol. 32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2022.112924_bib51","first-page":"247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"key":"10.1016\/j.biopha.2022.112924_bib52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"vol. 51","author":"Hutchings","year":"2019","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.biopha.2022.112924_bib53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ehjcvp\/pvz019","article-title":"Cardiovascular pharmacotherapy: A new ESC Handbook comprehensively addresses pharmacological treatment issues for patients with cardiovascular disease","volume":"vol. 5","author":"Kaski","year":"2019","journal-title":"Eur. Heart J. - Cardiovasc. Pharmacother."},{"key":"10.1016\/j.biopha.2022.112924_bib54","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.biopha.2022.112924_bib55","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.biopha.2022.112924_bib56","first-page":"50","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nat 2016 5377618"},{"key":"10.1016\/j.biopha.2022.112924_bib57","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1021\/acschemneuro.1c00394","article-title":"FDA Approval of Aduhelm Paves a New Path for Alzheimer\u2019s Disease","volume":"12","author":"Tanzi","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib58","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2021.11768","article-title":"Will CMS find aducanumab reasonable and necessary for alzheimer disease after fda approval?","volume":"326","author":"Schulman","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112924_bib59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes","volume":"vol. 120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.112924_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trci.2019.05.001","article-title":"Tackling gaps in developing life-changing treatments for dementia","volume":"vol. 5","author":"Mauricio","year":"2019","journal-title":"Alzheimer\u2019s Dement.: Transl. Res. Clin. Interv."},{"key":"10.1016\/j.biopha.2022.112924_bib61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"vol. 6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.biopha.2022.112924_bib62","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1570159X16666180315142137","article-title":"Current therapeutic molecules and targets in neurodegenerative diseases based on in silico drug design","volume":"16","author":"Sehgal","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of L-dopa: Why is it the gold standard Parkinson\u2019s disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib64","first-page":"229","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: an old drug still going strong","volume":"vol. 5","author":"Poewe","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.biopha.2022.112924_bib65","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","article-title":"Rotigotine transdermal patch: A review in Parkinson\u2019s disease","volume":"33","author":"Frampton","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2022.112924_bib66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00000441-197907000-00008","article-title":"Treatment of Parkinson\u2019s disease with dopamine agonists: A review","volume":"vol. 278","author":"Lieberman","year":"1979","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5694\/j.1326-5377.1978.tb77384.x","article-title":"Ergot derivatives for Parkinsonism","volume":"2","author":"Calne","year":"1979","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.biopha.2022.112924_bib68","first-page":"467","article-title":"Rasagiline - A novel MAO B inhibitor in Parkinson\u2019s disease therapy","volume":"vol. 3","author":"Lecht","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.biopha.2022.112924_bib69","doi-asserted-by":"crossref","first-page":"57316","DOI":"10.18632\/oncotarget.17622","article-title":"An updated meta-analysis of amantadine for treating dyskinesia in Parkinson\u2019s disease","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.112924_bib70","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the treatment of Parkinson\u2019s disease","volume":"vol. 4","author":"Schrag","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib71","first-page":"3","article-title":"New hopes and challenges for treatment of neurodegenerative disorders: Great opportunities for Young neuroscientists","volume":"4","author":"Kiaei","year":"2013","journal-title":"Basic Clin. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pnpbp.2010.07.018","article-title":"Novel insights for the treatment of Alzheimer\u2019s disease","volume":"35","author":"Kurz","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112924_bib73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","article-title":"Screening out irrelevant cell-based models of disease","volume":"vol. 15","author":"Horvath","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112924_bib74","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","article-title":"Neurodegenerative disease: Models, mechanisms, and a new hope","volume":"vol. 10","author":"Gitler","year":"2017","journal-title":"DMM Dis. Models Mech."},{"key":"10.1016\/j.biopha.2022.112924_bib75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-60327-258-2_12","article-title":"Use of primary human cells in high-throughput screens","volume":"565","author":"Dunne","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib76","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2022.112924_bib77","first-page":"277","article-title":"Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening","volume":"19","author":"Paricharak","year":"2018","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.biopha.2022.112924_bib78","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.1c00118","article-title":"DNA-encoded chemical libraries: A comprehensive review with succesful stories and future challenges","volume":"4","author":"Gironda-Mart\u00ednez","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib79","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.drudis.2018.01.010","article-title":"Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: How far can they be simplified?","volume":"23","author":"Mignani","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112924_bib80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","article-title":"ADMET modeling approaches in drug discovery","volume":"24","author":"Ferreira","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112924_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201800059","article-title":"Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches","volume":"37","author":"Hoffer","year":"2018","journal-title":"Mol. Inf."},{"key":"10.1016\/j.biopha.2022.112924_bib82","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"vol. 162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neurobiolaging.2019.02.008","article-title":"Using stem cell\u2013derived neurons in drug screening for neurological diseases","volume":"vol. 78","author":"Little","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2022.112924_bib84","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/nm1067","article-title":"Molecular pathways to neurodegeneration","volume":"10","author":"Bossy-Wetze","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000100355","article-title":"Amyloid-\u03b2 aggregation","volume":"vol. 4","author":"Finder","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.biopha.2022.112924_bib86","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/jpet.112.192138","article-title":"Mitochondrial dysfunction in neurodegenerative diseases","volume":"vol. 342","author":"Johri","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.112924_bib87","first-page":"376","article-title":"Oxidative stress in neurodegenerative diseases","volume":"7","author":"Chen","year":"2012","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2022.112924_bib88","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s10495-010-0481-0","article-title":"Molecular and cellular mechanisms of excitotoxic neuronal death","volume":"15","author":"Wang","year":"2010","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2022.112924_bib89","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1602\/neurorx.2.4.627","article-title":"New prospects and strategies for drug target discovery in neurodegenerative disorders","volume":"2","author":"Hilbush","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.biopha.2022.112924_bib90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3389\/fnins.2016.00375","article-title":"Key targets for multi-target ligands designed to combat neurodegeneration","volume":"10","author":"Ramsay","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057113499777","article-title":"Phenotypic screens targeting neurodegenerative diseases","volume":"vol. 19","author":"Zhang","year":"2014","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.biopha.2022.112924_bib92","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1021\/acs.jmedchem.9b00797","article-title":"Opportunities and challenges in phenotypic screening for neurodegenerative disease research","volume":"63","author":"Brown","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112924_bib93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1021\/cn500051h","article-title":"Back to the future with phenotypic screening","volume":"5","author":"Prior","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib94","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/17460441.2019.1623784","article-title":"Cell death assays for neurodegenerative disease drug discovery","volume":"vol. 14","author":"Linsley","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112924_bib95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.drudis.2020.02.006","article-title":"Structure-based view of the druggable genome","volume":"25","author":"Wang","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112924_bib96","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.15252\/embj.201797397","article-title":"<scp>APP<\/scp> mouse models for Alzheimer\u2019s disease preclinical studies","volume":"36","author":"Sasaguri","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2022.112924_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd2959","article-title":"Advances in tau-focused drug discovery for Alzheimer\u2019s disease and related tauopathies","volume":"vol. 8","author":"Brunden","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112924_bib98","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1471-4159.2004.02728.x","article-title":"Overexpression of \u03b1-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of \u03b1-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson\u2019s disease","volume":"91","author":"Yamada","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112924_bib99","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/acschemneuro.8b00242","article-title":"A focused library of psychotropic analogues with neuroprotective and neuroregenerative potential","volume":"10","author":"Uliassi","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acsmedchemlett.9b00039","article-title":"Harnessing polypharmacology with medicinal chemistry","volume":"10","author":"Bolognesi","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2022.112924_bib102","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrd3373","article-title":"Cell death assays for drug discovery","volume":"vol. 10","author":"Kepp","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112924_bib103","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/cdd.2009.44","article-title":"Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes","volume":"vol. 16","author":"Galluzzi","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.112924_bib104","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0165-0270(96)00146-X","article-title":"Dual staining assessment of Schwann cell viability within whole peripheral nerves using calcein-AM and ethidium homodimer","volume":"71","author":"Decherchi","year":"1997","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.biopha.2022.112924_bib105","article-title":"Measurement of cell death in mammalian","volume":"25","author":"Cummings","year":"2004","journal-title":"Cells Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-385493-3.00004-8","article-title":"Apoptosis and beyond: Cytometry in studies of programmed cell death","volume":"vol. 103","author":"Wlodkowic","year":"2011","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib107","first-page":"465","article-title":"Analysis of cell viability by the lactate dehydrogenase assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.biopha.2022.112924_bib108","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.1999.276.5.C1121","article-title":"Importance of glucose-6-phosphate dehydrogenase activity in cell death","volume":"276","author":"Tian","year":"1999","journal-title":"Am. J. Physiol. - Cell Physiol."},{"key":"10.1016\/j.biopha.2022.112924_bib109","doi-asserted-by":"crossref","DOI":"10.1177\/1179670717691251","article-title":"In Vitro Cell Death Determination for Drug Discovery: A landscape review of real issues","volume":"vol. 10","author":"M\u00e9ry","year":"2017","journal-title":"J. Cell Death"},{"key":"10.1016\/j.biopha.2022.112924_bib110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.toxrep.2020.02.002","article-title":"Real-time cell analysis system in cytotoxicity applications: Usefulness and comparison with tetrazolium salt assays","volume":"vol. 7","author":"Stefanowicz-Hajduk","year":"2020","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.biopha.2022.112924_bib111","doi-asserted-by":"crossref","first-page":"12347","DOI":"10.3390\/s120912347","article-title":"Multiple applications of alamar blue as an indicator of metabolic function and cellular health in cell viability bioassays","volume":"12","author":"Rampersad","year":"2012","journal-title":"Sens. (Switz. )"},{"key":"10.1016\/j.biopha.2022.112924_bib112","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0958-1669(00)00177-4","article-title":"Cytotoxicity tests for high-throughput drug discovery","volume":"vol. 12","author":"Slater","year":"2001","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.biopha.2022.112924_bib113","first-page":"279","article-title":"Apoptosis assays","volume":"129","author":"Oancea","year":"2006","journal-title":"Methods Mol. Med"},{"key":"10.1016\/j.biopha.2022.112924_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21239090","article-title":"Do TUNEL and other apoptosis assays detect cell death in preclinical studies?","volume":"vol. 21","author":"Mirzayans","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/08916930701356978","article-title":"HMGB1: A signal of necrosis","volume":"vol. 40","author":"Raucci","year":"2007","journal-title":"Autoimmunity"},{"key":"10.1016\/j.biopha.2022.112924_bib116","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","article-title":"Basic mechanisms of neurodegeneration: A critical update","volume":"14","author":"Jellinger","year":"2010","journal-title":"J. Cell. Mol. Med"},{"key":"10.1016\/j.biopha.2022.112924_bib117","first-page":"1086","article-title":"SH-SY5Y human neuroblastoma cell line: In vitro cell model of dopaminergic neurons in Parkinson\u2019s disease","volume":"vol. 123","author":"Xie","year":"2010","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.biopha.2022.112924_bib118","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/795375","article-title":"Amyloid beta: Multiple mechanisms of toxicity and only some protective effects?","volume":"2014","author":"Carrillo-Mora","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2022.112924_bib119","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.3390\/ijms21124477","article-title":"The Toxicity and Polymorphism of \u03b2-Amyloid Oligomers","volume":"21","author":"Huang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib120","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","article-title":"Towards an understanding of amyloid-\u03b2 oligomers: characterization, toxicity mechanisms, and inhibitors","volume":"46","author":"Lee","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2022.112924_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071884","article-title":"Cellular receptors of amyloid \u03b2 oligomers (A\u03b2Os) in Alzheimer\u2019s disease","volume":"vol. 19","author":"Mroczko","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib122","doi-asserted-by":"crossref","first-page":"12463","DOI":"10.1074\/jbc.R109.080895","article-title":"Calcium signaling and amyloid toxicity in Alzheimer disease","volume":"vol. 285","author":"Demuro","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112924_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011820","article-title":"Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property","volume":"5","author":"Sepulveda","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112924_bib124","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"vol. 33","author":"Kayed","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.biopha.2022.112924_bib125","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.bmc.2011.05.021","article-title":"Neuroprotective effects of linarin through activation of the PI3K\/Akt pathway in amyloid-\u03b2-induced neuronal cell death","volume":"19","author":"H","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112924_bib126","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14728222.2019.1702972","article-title":"Emerging roles of N- and C-terminally truncated A\u03b2 species in Alzheimer\u2019s disease","volume":"23","author":"Wirths","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2022.112924_bib127","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12038-009-0033-3","article-title":"Rapid aggregation and assembly in aqueous solution of A \u03b2 (25\u201335) peptide","volume":"34","author":"Millucci","year":"2009","journal-title":"J. Biosci."},{"key":"10.1016\/j.biopha.2022.112924_bib128","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009316","article-title":"A guide to neurotoxic animal models of Parkinson\u2019s disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson\u2019s disease","volume":"vol. 65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib130","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","article-title":"Mechanism of toxicity in rotenone models of Parkinson\u2019s disease","volume":"23","author":"Sherer","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuro.2010.04.006","article-title":"Mechanisms of rotenone-induced proteasome inhibition","volume":"31","author":"Chou","year":"2010","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.biopha.2022.112924_bib132","unstructured":"Sian, J., Youdim, M., Riederer, P. & Gerlach, M. Neurotransmitters and Disorders of the Basal Ganglia. (1999)."},{"key":"10.1016\/j.biopha.2022.112924_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-017-0149-0","article-title":"The SH-SY5Y cell line in Parkinson\u2019s disease research: A systematic review","volume":"vol. 12","author":"Xicoy","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2022.112924_bib134","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12640-019-00038-6","article-title":"Anti-inflammatory activity of ursolic acid in MPTP-induced parkinsonian mouse model","volume":"36","author":"Rai","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2022.112924_bib135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fphar.2018.00757","article-title":"Effect of chlorogenic acid supplementation in MPTP-intoxicated mouse","volume":"9","author":"Singh","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112924_bib136","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchemneu.2015.12.002","article-title":"Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model","volume":"71","author":"Rai","year":"2016","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.biopha.2022.112924_bib137","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1007\/s12035-019-1605-3","article-title":"Cholinergic differentiation of human neuroblastoma SH-SY5Y cell line and its potential use as an in vitro model for alzheimer\u2019s disease studies","volume":"56","author":"de Medeiros","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib138","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","article-title":"Converging pathways in neurodegeneration, from genetics to mechanisms","volume":"21","author":"Gan","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib139","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fcell.2020.00328","article-title":"In vitro Models of Neurodegenerative Diseases","volume":"vol. 8","author":"Slanzi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib140","article-title":"Translational animal models for Alzheimer\u2019s disease: An Alzheimer\u2019s association business consortium think tank","volume":"6","author":"Vitek","year":"2020","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Inter."},{"key":"10.1016\/j.biopha.2022.112924_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1818","article-title":"Mouse models of neurodegeneration: Know your question, know your mouse","volume":"11","author":"Fisher","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib142","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/03639040500216246","article-title":"Cell lines as in vitro models for drug screening and toxicity studies","volume":"31","author":"Allen","year":"2005","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2022.112924_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081098","article-title":"Cancer cell lines are useful model systems for medical research","volume":"vol. 11","author":"Mirabelli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.112924_bib144","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/03602532.2011.605791","article-title":"Metabolic activation in drug-induced liver injury","volume":"44","author":"Leung","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biopha.2022.112924_bib145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1087057105283787","article-title":"Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2","volume":"11","author":"Miret","year":"2006","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.biopha.2022.112924_bib146","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00204-020-02763-w","article-title":"The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development","volume":"vol. 94","author":"Walker","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2022.112924_bib147","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1042\/BST0381051","article-title":"Human pluripotent stem cells in drug discovery and predictive toxicology","volume":"vol. 38","author":"Laustriat","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.biopha.2022.112924_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111188","article-title":"Towards improved hepatocyte cultures: Progress and limitations","volume":"138","author":"Ruo\u00df","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biopha.2022.112924_bib149","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10571-019-00653-z","article-title":"Recent expansions on cellular models to uncover the scientific barriers towards drug development for Alzheimer\u2019s disease","volume":"vol. 39","author":"Dubey","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112924_bib150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-62703-640-5_2","article-title":"Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology","volume":"1078","author":"Kovalevich","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib151","doi-asserted-by":"crossref","first-page":"36377","DOI":"10.1371\/journal.pone.0036377","article-title":"Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines","volume":"7","author":"Zhu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112924_bib152","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF02618461","article-title":"The fine structure of continuous human neuroblastoma lines SK-N-SH, SK-N-BE(2), and SK-N-MC","volume":"17","author":"Barnes","year":"1981","journal-title":"In Vitro"},{"key":"10.1016\/j.biopha.2022.112924_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6446(02)02386-3","article-title":"Applications of transfected cell microarrays in high-throughput drug discovery","volume":"vol. 7","author":"Bailey","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112924_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00137","article-title":"Targeting amyloidogenic processing of APP in Alzheimer\u2019s disease","volume":"vol. 13","author":"Zhao","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib155","article-title":"& Skibinski. Drug discovery in Parkinson\u2019s disease: update and developments in the use of cellular models","volume":"15","author":"Finkbeiner","year":"2011","journal-title":"Int. J. High. Throughput Screen."},{"key":"10.1016\/j.biopha.2022.112924_bib156","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/JEN.S25100","article-title":"A simple model to study tau pathology","volume":"10","author":"Houck","year":"2016","journal-title":"J. Exp. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib157","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/jnc.14806","article-title":"Cellular models of alpha\u2010synuclein toxicity and aggregation","volume":"150","author":"Delenclos","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112924_bib158","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2022.112924_bib159","doi-asserted-by":"crossref","unstructured":"Iwanami, S. & Iwami, S. Quantitative immunology by data analysis using mathematical models. in Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics vols 1\u20133 984\u2013992 (Elsevier, 2018).","DOI":"10.1016\/B978-0-12-809633-8.20250-1"},{"key":"10.1016\/j.biopha.2022.112924_bib160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.1990.70.2.513","article-title":"Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system","volume":"vol. 70","author":"Nicoll","year":"1990","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2022.112924_bib161","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000174","article-title":"Neuronal differentiation of LUHMES cells induces substantial changes of the proteome","volume":"21","author":"T\u00fcshaus","year":"2021","journal-title":"Proteomics"},{"key":"10.1016\/j.biopha.2022.112924_bib162","first-page":"195","article-title":"A novel method of neural differentiation of PC12 cells by using Opti-MEM as a basic induction medium","volume":"41","author":"Hu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib163","first-page":"53193","article-title":"Differentiation of the SH-SY5Y human neuroblastoma cell line","volume":"2016","author":"Shipley","year":"2016","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2022.112924_bib164","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.mcn.2018.02.006","article-title":"New insights on Parkinson\u2019s disease from differentiation of SH-SY5Y into dopaminergic neurons: An involvement of aquaporin4 and 9","volume":"88","author":"Avola","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neulet.2008.07.079","article-title":"Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype","volume":"443","author":"Kume","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2022.112924_bib166","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186636","article-title":"In situ fibrillizing amyloid-beta 1-42 induces neurite degeneration and apoptosis of differentiated SH-SY5Y cells","volume":"12","author":"Krishtal","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112924_bib167","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1021\/acschemneuro.0c00011","article-title":"Molecular mechanism of apoptosis by Amyloid \u03b2-Protein fibrils formed on neuronal cells","volume":"11","author":"Takada","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib168","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2019.01.007","article-title":"Induced pluripotent stem cells for neural drug discovery","volume":"vol. 24","author":"Farkhondeh","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112924_bib169","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2020.09.013","article-title":"Towards advanced iPSC-based drug development for neurodegenerative disease","volume":"27","author":"Pasteuning-Vuhman","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2022.112924_bib170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14012","article-title":"Human pluripotent stem cell\u2013derived models and drug screening in CNS precision medicine","volume":"vol. 1471","author":"Silva","year":"2020","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib171","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13238-010-0027-9","article-title":"Cellular models for disease exploring and drug screening","volume":"vol. 1","author":"Li","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.biopha.2022.112924_bib172","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2958210","article-title":"Human embryonic stem cells: A model for the study of neural development and neurological diseases","volume":"2016","author":"Prajumwongs","year":"2016","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.biopha.2022.112924_bib173","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCRESAHA.114.303043","article-title":"Perspectives for induced pluripotent stem cell technology","volume":"114","author":"Nagata","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2022.112924_bib174","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.stemcr.2016.10.003","article-title":"Detecting genetic mosaicism in cultures of human pluripotent stem cells","volume":"7","author":"Baker","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.biopha.2022.112924_bib175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10072-014-1989-9","article-title":"Neurodegenerative diseases in a dish: the promise of iPSC technology in disease modeling and therapeutic discovery","volume":"36","author":"Xie","year":"2015","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib176","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5838934","article-title":"Generation of cholinergic and dopaminergic interneurons from human pluripotent stem cells as a relevant tool for in vitro modeling of neurological disorders pathology and therapy","volume":"vol. 2016","author":"Ochalek","year":"2016","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biopha.2022.112924_bib177","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/cells9092018","article-title":"A Simple differentiation protocol for generation of induced pluripotent stem cell-derived basal forebrain-like cholinergic neurons for alzheimer\u2019s disease and frontotemporal dementia disease modeling","volume":"9","author":"Mu\u00f1oz","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.112924_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17165-w","article-title":"Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease","volume":"11","author":"Doi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.112924_bib179","doi-asserted-by":"crossref","unstructured":"Schweitzer, J.S. et al. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson\u2019s Disease. https:\/\/doi.org\/10.1056\/NEJMoa1915872 382, 1926\u20131932 (2020).","DOI":"10.1056\/NEJMoa1915872"},{"key":"10.1016\/j.biopha.2022.112924_bib181","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.biopha.2022.112924_bib182","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.23571","article-title":"Neuroinflammation in the central nervous system: Symphony of glial cells","volume":"67","author":"Yang","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2022.112924_bib183","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat","volume":"17","author":"Leng","year":"2020","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.biopha.2022.112924_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00728-4","article-title":"Applications of brain organoids in neurodevelopment and neurological diseases","volume":"28","author":"Sun","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2022.112924_bib185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcdb.2020.05.012","article-title":"Modelling neurodegenerative disease using brain organoids","volume":"111","author":"Wray","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2022.112924_bib186","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41380-019-0500-7","article-title":"Three-dimensional modeling of human neurodegeneration: Brain organoids coming of age","volume":"25","author":"Grenier","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112924_bib187","doi-asserted-by":"crossref","DOI":"10.3390\/mi10030165","article-title":"Engineering microfluidic organoid-on-a-chip platforms","volume":"10","author":"Yu","year":"2019","journal-title":"Micromachines"},{"key":"10.1016\/j.biopha.2022.112924_bib188","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nature13800","article-title":"A three-dimensional human neural cell culture model of Alzheimer\u2019s disease","volume":"515","author":"Choi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112924_bib189","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/14737175.2016.1166053","article-title":"Developments in 3D neural cell culture models: The future of neurotherapeutics testing?","volume":"16","author":"Ko","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2022.112924_bib190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/17460441.2020.1703671","article-title":"Organoid and pluripotent stem cells in Parkinson\u2019s disease modeling: An expert view on their value to drug discovery","volume":"15","author":"Marotta","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112924_bib191","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41593-018-0175-4","article-title":"A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer\u2019s disease","volume":"21","author":"Park","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2022.112924_bib192","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1818","article-title":"Mouse models of neurodegeneration: Know your question, know your mouse","volume":"vol. 11","author":"Fisher","year":"2019","journal-title":"Sci. Transl. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222003134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222003134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:19:01Z","timestamp":1774250341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222003134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":191,"alternative-id":["S0753332222003134"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112924","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell models for Alzheimer\u2019s and Parkinson\u2019s disease: At the interface of biology and drug discovery","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112924"}}